Zheng D, Thomas J 3rd. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer. Breast Cancer Res Treat 2023 Jun 16. doi: 10.1007/s10549-023-06992.
PMID: 37326766